Moderna, Inc. (MRNA) research: valuation against peers, fundamentals over time, risk and news coverage
MRNA
Moderna, Inc.No data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYNEUTRALModerna Set to Join Nasdaq-100, Replacing Warner Bros. Discovery
Moderna will replace Warner Bros. Discovery in the Nasdaq-100 index on October 9, triggering mechanical buying and selling from index-tracking funds.
- BREAKING STORYBEARISHBiotech Downgrades Hit Ultragenyx on Trial Failure, Moderna on Valuation
Two separate analyst downgrades hit biotech stocks, with Ultragenyx cut on a clinical trial failure and Moderna cut on valuation grounds.
- BREAKING STORYBEARISHModerna Shares Fall After Company Prices $2 Billion Convertible Notes Offering
Moderna's stock dropped after the company announced a $2 billion convertible notes offering, a financing move that raises the prospect of future share dilution.
- BREAKING STORYBULLISHModerna Cancer-Vaccine Data Ignites Broad Biopharma Re-Rating
Moderna's cancer-vaccine breakthrough triggered a sector-wide rally in biopharma stocks, accelerating an upswing that had already begun to reverse years of underperformance. The data point revives the platform thesis for mRNA beyond infectious disease and pulls capital back toward clinical-stage names including smaller RNA-therapeutics developers.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.